The discerning eye, however, seeks not merely to avoid losses, but to identify those assets capable of generating a sustained, if modest, return – a cryptographic dividend, as it were. And so, we shall examine one token worthy of cautious consideration, and another best left to gather digital dust.
The story begins, as many do, with a name change. It was once Avago, you see, before it absorbed the original Broadcom back in 2016. A bit like a particularly ambitious amoeba, really. They then decided to keep the Broadcom name, which is perfectly logical if you’re a large corporation. For years, they made a vast array of chips – the tiny, essential components that power pretty much everything these days – for mobile phones, data centers, networking equipment, and a whole host of other things. It’s a surprisingly diverse business, chipmaking. You wouldn’t think so, staring at a silicon wafer, but there’s a lot going on.
They are small and swift, the temporary holders of gigantic dreams, who, with a few careless flicks of a mouse, now watch their portfolios hemorrhage into the abyss of unrealised loss. Darkfost, a stern but insightful writer chronicling the cryptic paths of our era, has set a fine lens upon this phenomenon, pointing a meticulous eye to the swelling body of paper losses that the new marine giants carry in their digital caves.
They’ve laid out this little “snapshot.” VXUS, a paltry 0.05% expense ratio. IEMG, a slightly more aggressive 0.09%. It’s like choosing between two different brands of sandpaper when you’re being slowly eroded. And the one-year returns? 33.16% for VXUS, 38.88% for IEMG. Fantastic. As if past performance is any indication of future results. It’s statistically meaningless, you know? It’s like saying because I had a good tuna sandwich yesterday, I’m guaranteed a good day today. Ridiculous.
The Guild of Alchemists1 (otherwise known as investment managers) are forever concocting these “ETFs.” Essentially, they’re baskets of shares, pre-arranged for your convenience. SPGM aims for the entire planetary market, a truly ambitious undertaking. IEFA, however, is more… selective. It focuses on the developed nations outside of North America. Think Europe, Asia, Australia – places with slightly more established plumbing, generally speaking.
This isn’t a celebration of prosperity, mind you. It’s a reckoning. A look at what these funds offer, stripped of the polished promises. Cost, yield, risk… these are the levers that move the world, and we, the observers, must understand them.
The facts, as laid out in a filing with the Securities and Exchange Commission, are these: Commodore Capital, after a period of faithful stewardship, sold every single one of its 2,338,287 Agios shares. The consequence? A diminution of the firm’s holdings to the tune of $93.86 million. A decidedly sticky wicket, as the cricketers might say. One can only assume they’ve discovered a more promising investment – perhaps a scheme involving trained pigeons and the delivery of miniature muffins.
Commodore Capital, a name whispered with a mixture of respect and weary resignation within the walled gardens of venture capital, had quietly, almost apologetically, dissolved its entire stake in the company – a holding of 3,200,000 shares, amounting to an estimated $69.06 million. The transaction, recorded with the bureaucratic precision of a priest documenting a death, was less a dramatic exit and more a slow, deliberate fading, like a photograph left too long in the sun.
For years, Lilly has been a reliable purveyor of remedies for a common affliction: excessive sugar in the bloodstream. A solid business, if you don’t dwell on the reasons for its existence. But recently, they’ve stumbled upon a far more lucrative field: the art of diminishing one’s physical dimensions. Zepbound, they call it. A rather grand name for a substance that encourages people to eat less. It’s become quite the sensation, this Zepbound, even outselling its diabetic cousin, Mounjaro. The world, it appears, is eager to be lighter. And Lilly, ever the astute merchant, is only too happy to oblige.
The market, that fickle mistress, appears to have demanded a more decisive victory. Investors, it seems, prefer their miracles to be unequivocally miraculous, not merely… effective. The stock, predictably, has suffered a decline – a reminder that the pursuit of profit is often less about genuine progress and more about exceeding expectations, however absurd.